Macrophage-directed immunotherapy as adjuvant to photodynamic therapy of cancer
1997

Macrophage-Directed Immunotherapy with Photodynamic Therapy for Cancer

Sample size: 32 publication Evidence: high

Author Information

Author(s): M Korbelik, VR Naraparaju, N Yamamoto

Primary Institution: British Columbia Cancer Agency, Vancouver, BC, Canada

Hypothesis

Can macrophage-activating factor enhance the effectiveness of photodynamic therapy in treating cancer?

Conclusion

The study found that combining macrophage-activating factor with photodynamic therapy significantly improved tumor cure rates.

Supporting Evidence

  • DBPMAF treatment increased tumor cure rates from 25% to 100% when combined with PDT.
  • DBPMAF therapy reduced PDT-induced immunosuppression in treated mice.
  • Multiple DBPMAF treatments were more effective than single treatments.

Takeaway

This study shows that a special treatment can help a light therapy work better against cancer in mice.

Methodology

Mice with SCCVII tumors were treated with photodynamic therapy followed by injections of macrophage-activating factor at specific intervals.

Limitations

The study was conducted on mice, which may not fully represent human responses.

Participant Demographics

8-12-week-old syngeneic C3H/HeN mice

Statistical Information

P-Value

p<0.001

Statistical Significance

p<0.001

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication